[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"high-risk-hpv-any-strain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:high-risk-hpv-any-strain":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,63],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":62},"100636954","phase-2-phase-ii-study-of-dysplasix-intravaginal-suppositories-in-patients-patients-with-high-risk-hpv-and-mild-cervical-cytologic-abnormalities-100636954",false,"NCT07572396","Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities","A Phase II, Randomized, Double-blind, Placebo-Controlled, Proof of Concept Study to Assess the Safety and Efficacy of Dysplasix™ Intravaginally-Administered Suppositories in Patients With High-Risk Human Papillomavirus (Hr-HPV) as Determined by HPV Testing, and Accompanied by Either (1) Atypical Squamous Cells of Undetermined Significance (ASC-US) or (2) Low-Grade Squamous Intraepithelial Lesions (LSIL), as Determined by Cytology","Inclusion Criteria:\n\nParticipants must meet all the following criteria to be eligible to enroll in the study:\n\n1. Participants capable of giving informed consent\n2. Females, ages 18 to 65 years old at the time of signature of the informed consent form.\n3. Participants who are able to correctly self-administer the intravaginal suppositories\n4. One or more hr-HPV oncotypes as confirmed by HPV test\n5. Participants with ASCUS or LSIL abnormalities as confirmed by cytology\n6. Immune competent\n7. Participants of childbearing potential must have a negative pregnancy test at screening.\n8. Participants of childbearing potential must agree to use appropriate contraception or abstain from sexual intercourse for the duration of the study\n9. Participants must not have received a recent HPV vaccination and must abstain from HPV vaccination until the end of study\n\nExclusion Criteria:\n\nParticipants meeting any of the following criteria will be excluded from the study:\n\n1. Presence of HSIL at screening cytology\n2. Evidence of glandular abnormalities (AGC\u002FAIS) at screening cytology\n3. BMI below 16\n4. Pregnant or nursing females\n5. Evidence of vaginal\u002Fvulval comorbidities, specifically, common sexually transmitted or vaginal infections, and bloodborne pathogens\n6. Using a vaginal contraceptive ring\n7. History of irregular menstrual cycles or routine intermenstrual bleeding\n8. Active autoimmune disease\n9. Taking prohibited concomitant medications\n10. Concurrent malignancy except for non-melanoma skin lesions\n11. Active participation in another clinical trial involving therapeutic intervention (unless ending within 30 days of screening date)","FEMALE","18 Years","65 Years",{"count":20,"type":21},45,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to learn if an investigational vaginal suppository therapy works to treat low-grade cervical lesions (ASC-US and LSIL) associated with high-risk human papillomavirus (hr-HPV) infection in women. It will also learn about the safety and tolerability of this investigational therapy. The main questions it aims to answer are:\n\n* Does the investigational therapy lead to regression of cervical lesions?\n* Does the investigational therapy help clear hr-HPV infection?\n* Do any adverse effects occur from using this medical product?\n\nResearchers will compare the investigational therapy to a placebo (a look-alike substance that contains no active drug) to see if the investigational therapy works.\n\nParticipants will:\n\n* Be screened for hr-HPV, cervical abnormalities, and other conditions to be assessed for eligibility\n* Self-administer 15 doses of the investigational therapy or placebo as a vaginal suppository over 19 calendar days\n* Attend scheduled clinic visits for examinations, testing, and monitoring for a period of two months\n* Undergo assessments to evaluate cervical lesion status, hr-HPV infection, and safety outcomes\n* Keep a daily diary of investigational therapy use and associated information",[27,28,29,30,31,32],"High-risk HPV (Any Strain)","LSIL, Low Grade Squamous Intraepithelial Lesion","ASC-US","HPV Infection","Cervical Abnormalities","Uterine Cervical Dysplasia",[34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49],"hpv","human papillomavirus","CIN1","LSIL","EGCG","Quinine Sulfate","abnormal Pap","ASCUS","gynecology","precancerous lesions","atypical squamous cells","low grade squamous intraepithelial lesions","Epigallocatechin gallate","women's health","abnormal cytology","cervical cytology","RECRUITING","2026-05-12",{"date":53,"type":54},"2026-05-14","ACTUAL",{"date":56,"type":21},"2026-04-30",{"date":58,"type":21},"2027-01-27",{"name":60,"class":61},"Amplexd Therapeutics, Inc.","INDUSTRY",1,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":74,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":62},"100616295","phase-2-study-assessing-reduced-hpv-infectivity-and-transmission-in-hpv-positive-women-following-vaccination-with-9vhpv-100616295","NCT07303751","Study Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPV","HPV Vaccination and Infectivity Reduction in HPV-positive Women","RIFT-SSA","Inclusion Criteria:\n\n* Born female\n* Aged between 18-29 years old;\n* Living in Kambia district (or neighbouring district if included) without plans to move away in the next 12 months;\n* Willing to participate in the study and have signed the informed consent form;\n* In good health as determined by a medical history (a physical examination will be conducted if necessary according to the clinician's judgement);\n* Willing to be tested for HIV;\n* Are HIV negative at the screening visit;\n* Not pregnant;\n* Able to pass a Test of Understanding (TOU);\n* Willing to provide cervical, urine and blood samples;\n* Agree to be vaccinated with a single dose of Gardasil9® if randomised to the vaccine arm at Day 0;\n* Have no visible suspicious cervical lesions on examination.\n* Agree to a pregnancy test at screening and before any HPV vaccination.\n\nExclusion Criteria:\n\n* They have been previously vaccinated against HPV;\n* They have a chronic condition, such as autoimmune conditions, degenerative diseases, neurologic or genetic diseases among others;\n* They are HIV positive or immunocompromised;\n* They are pregnant or planning to get pregnant in the next 12 months;\n* They are less than three months post-partum or currently breastfeeding;\n* They are allergic to one of the vaccine components or to latex;\n* They are sexually active and are not using, or are not willing to use, an effective birth control method from D-14 until 60 days after the last vaccine dose\n* The nurse or clinician determining the eligibility, in agreement with principal investigator, considers that there is a reason that precludes participation.","29 Years",{"count":73,"type":21},80,[24],"This is a randomized, open-label trial, to assess whether a single dose of HPV nonavalent vaccine, administered to HIV uninfected, unvaccinated women with high risk HPV16\u002F18\u002F31\u002F33\u002F45\u002F52 or 58 can decrease the infectivity of shed HPV viruses.\n\nOur hypothesis is that vaccination will have little or no impact on HPV sample positivity by DNA PCR since the viral particles will continue to be produced and released, but that particles will be neutralized by vaccine-induced antibodies, thereby reducing their infective capacity. Cervical samples will be collected at randomisation and at 6 months, to compare infectivity of shed HPV viruses.",[77,27,78],"HPV","Human Papillomavirus (HPV) Infections",[80,81,82,78,83,84,85,86,87,88,89],"Cervical cancer","Cervical Intraepithelial Neoplasia Grade I\u002F II\u002F III (CIN I\u002FII\u002FIII)","Squamous Intraepithelial Lesions of the Cervix, High\u002F Low Grade","High-risk HPV","HPV-16\u002F 18","HPV DNA Tests","HPV Vaccines","HPV Nonavalent Vaccine","Gardasil-9","9vHPV","NOT_YET_RECRUITING","2026-02-09",{"date":93,"type":54},"2026-02-11",{"date":95,"type":21},"2026-02-01",{"date":97,"type":21},"2027-02-01",{"name":99,"class":100},"Institut d'Investigació Biomèdica de Bellvitge","OTHER"]